Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701615 | 1.00 | CA1 (0.41) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL5835344 | 0.87 | CA1 (0.41) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL4867443 | 0.82 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL14254599 | 0.82 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL3201443 | 0.76 | KMT2A (0.63) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL15101846 | 0.76 | KMT2A (0.63) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL4705442 | 0.73 | KAT2B (0.39) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4705445 | 0.73 | KAT2B (0.39) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14254577 | 0.73 | KAT2B (0.39) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4988345 | 0.69 | AR (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087636-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-01-26 | — | — | US | disclosed |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CA1 4430/4885CA2 4765/4885KMT2A 1887/4885 |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CA1 4430/4885CA2 4765/4885KMT2A 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.